Cargando…

Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3

BACKGROUND: Most current guidelines do not recommend the serial analysis of tumour marker CA 15.3 in the follow-up of asymptomatic patients treated for early breast cancer (EBC). These guidelines are based on small-scale studies carried out in an era with more limited treatment options than today. I...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Cock, L., Heylen, J., Wildiers, A., Punie, K., Smeets, A., Weltens, C., Neven, P., Billen, J., Laenen, A., Wildiers, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282974/ https://www.ncbi.nlm.nih.gov/pubmed/34271308 http://dx.doi.org/10.1016/j.esmoop.2021.100203

Ejemplares similares

Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy
por: Hatse, Sigrid, et al.
Publicado: (2022)

Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape
por: Adams, E., et al.
Publicado: (2021)

Correlation of TROP-2 expression with clinical–pathological characteristics and outcome in triple-negative breast cancer
por: Izci, Hava, et al.
Publicado: (2022)

The impact of body mass index on age at breast cancer diagnosis and breast cancer phenotype
por: Brouckaert, Olivier, et al.
Publicado: (2015)

Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty
por: Bailur, Jithendra Kini, et al.
Publicado: (2017)

Biological ageing and frailty markers in breast cancer patients
por: Brouwers, Barbara, et al.
Publicado: (2015)

Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer
por: Lambrechts, Yentl, et al.
Publicado: (2023)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Vos, Hanne, et al.
Publicado: (2021)

Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy
por: Dalmasso, Bruna, et al.
Publicado: (2018)

Matrix Metalloproteinase Expression Patterns in Luminal A Type Breast Carcinomas
por: Decock, J., et al.
Publicado: (2007)

Differences in the Tumor Molecular and Microenvironmental Landscape between Early (Non-Metastatic) and De Novo Metastatic Primary Luminal Breast Tumors
por: Lambrechts, Yentl, et al.
Publicado: (2023)

Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition?
por: Van Baelen, Karen, et al.
Publicado: (2023)

Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA.
por: Gion, M., et al.
Publicado: (1994)

Age‐related remodelling of the blood immunological portrait and the local tumor immune response in patients with luminal breast cancer
por: Berben, Lieze, et al.
Publicado: (2020)

Is the sentinel lymph node biopsy more sensitive for the identification of positive lymph nodes in breast cancer than the axillary lymph node dissection?
por: Smeets, Ann, et al.
Publicado: (2013)

Oncological safety of autologous breast reconstruction after mastectomy for invasive breast cancer
por: Geers, Joachim, et al.
Publicado: (2018)

Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases
por: Nicolini, Andrea, et al.
Publicado: (2006)

Update on triple-negative breast cancer: prognosis and management strategies
por: Brouckaert, Olivier, et al.
Publicado: (2012)

Sequential Intra-arterial Infusion of (90)Y-resin Microspheres and Mitomycin C in Chemo Refractory Liver Metastatic Breast Cancer Patients: a Single Centre Pilot Study
por: Aarts, Brigitte Maximiliana, et al.
Publicado: (2020)

Impact of tumor chronology and tumor biology on lymph node metastasis in breast cancer
por: Smeets, Ann, et al.
Publicado: (2013)

The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases.
por: Gion, M., et al.
Publicado: (1991)

CA15.3 Serum Concentrations in Older Women with Infiltrating Ductal Carcinomas of the Breast
por: Ruibal, Álvaro, et al.
Publicado: (2014)

Dynamic alterations of immunosenescence-related genes in older women with breast cancer receiving chemotherapy: A prospective study
por: Wu, Qi, et al.
Publicado: (2022)

Blood Immunosenescence Signatures Reflecting Age, Frailty and Tumor Immune Infiltrate in Patients with Early Luminal Breast Cancer
por: Berben, Lieze, et al.
Publicado: (2021)

Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients
por: Bahrami-Ahmadi, Amir, et al.
Publicado: (2012)

Validation of a prognostic scoring system for postmastectomy locoregional recurrence in breast cancer()
por: Van der Vorst, Aline, et al.
Publicado: (2022)

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors
por: Sottotetti, Federico, et al.
Publicado: (2022)

Cause of death for patients with breast cancer: discordance between death certificates and medical files, and impact on survival estimates
por: Izci, Hava, et al.
Publicado: (2021)

Circulating MicroRNAs as Easy-to-Measure Aging Biomarkers in Older Breast Cancer Patients: Correlation with Chronological Age but Not with Fitness/Frailty Status
por: Hatse, Sigrid, et al.
Publicado: (2014)

Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in Relation to Ovarian Cancer Risk and Survival
por: Williams, Kristina A., et al.
Publicado: (2014)

An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies
por: Perrier, Alexandre, et al.
Publicado: (2020)

Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA?
por: Ginguay, Antonin, et al.
Publicado: (2022)

Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer--a comparison with CA15.3.
por: Dixon, A. R., et al.
Publicado: (1993)

Mortality and Major Adverse Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy: The First Decade
por: Jacobs, Johanna E. J., et al.
Publicado: (2023)

Relevance of hydroxyproline excretion to bone metastasis in breast cancer.
por: Gielen, F., et al.
Publicado: (1976)

Monitoring of postoperative neutrophil-to-lymphocyte ratio, D-dimer, and CA153 in: Diagnostic value for recurrent and metastatic breast cancer
por: Ren, Zhiyao, et al.
Publicado: (2023)

The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters
por: Brouwers, Barbara, et al.
Publicado: (2016)

Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.
por: Molina, R., et al.
Publicado: (1996)

Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study
por: van Walle, L., et al.
Publicado: (2021)

Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1/2: A Review of Secondary Prevention Guidelines
por: Dullens, Boudewijn, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jqq6h7jhtgf6nr7t7gvspegoue